Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971181 | 0.80 | ATM (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL971611 | 0.79 | MAPT (0.39) | TLR2TLR1 | |
| SCHEMBL23093861 | 0.77 | GAA (0.40) | TLR2TLR1PSEN1PSEN2APH1B | |
| SCHEMBL16914028 | 0.76 | TLR2 (0.48) | TLR2TLR1PSEN1PSEN2APH1B | |
| SCHEMBL29679548 | 0.74 | GAA (0.60) | TLR2TLR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27828829 | 0.74 | HCAR1 (0.47) | KMT2ASMN1; SMN2 | |
| SCHEMBL13807644 | 0.73 | MAPT (0.49) | MEN1KMT2ASMN1; SMN2TXNRD1GAA | |
| SCHEMBL2824263 | 0.73 | PSEN1 (0.44) | TLR2TLR1PSEN1PSEN2APH1B | |
| SCHEMBL22199017 | 0.72 | CYP1A2 (0.59) | PSEN1SMN1; SMN2GAA | |
| SCHEMBL15442425 | 0.72 | TLR2 (0.48) | TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2225248-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Wyeth LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | PDE12, PDE5A, PDE10A | TLR2 4611/4885TLR1 3763/4885PSEN1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.